--- title: "GLP-1 Injection Site Rotation: What a Six-Month Log Shows | Peptyn" description: "What the research actually says about injection site rotation and lipohypertrophy, and why six months of GLP-1 injection records is worth bringing to your prescriber." canonical: "https://peptyn.orlyn.ai/articles/glp1-injection-site-rotation-log" last-updated: "2026-08-16" --- # GLP-1 Injection Site Rotation: What a Six-Month Log Shows *What the research actually says about injection site rotation and lipohypertrophy, and why six months of GLP-1 injection records is worth bringing to your prescriber.* Educational · Not medical advice · 18+ Search for an injection site rotation chart and you will find dozens of diagrams: a torso divided into numbered squares, arrows pointing week to week, a grid to follow. Almost none of them tell you where the pattern came from, which drug it was studied in, or what to do when your own record does not match it. Published 15 August 2026 · 6 min read · 6 sources This article does the opposite. It does not give you a pattern to follow. Your prescribing information and your prescriber decide that. What it does is show you what the published research actually found, which drugs it was found in, and what six months of your own site records lets you put in front of a clinician that nothing else can. ## What a rotation chart is, and what a log is A rotation chart is a plan. It is a diagram of where injections are supposed to go, printed before anything happens. A log is a record. It is where injections actually went, written down as they happened. Those are different objects, and the second one is the one a clinician cannot reconstruct without you. They can hand you a chart at any appointment. They cannot go back and recover six months of your actual behavior from memory, yours or theirs. ## What the research found about repeated injections in one area The clinical concern behind every rotation chart is *lipohypertrophy*. StatPearls describes it as "a thickened 'rubbery' tissue swelling that can be picked up by a directed, accurate physical examination," and notes that "an inspection alone is not sufficient and concerned areas should be palpated to evaluate for lipohypertrophy."[1] That detail matters for anyone tracking at home: this is a finding of a hands-on exam, not something you diagnose by looking in a mirror. A widely cited prevalence study examined 430 outpatients who inject insulin. A diabetes nurse examined each patient's injection sites after they completed a questionnaire about their technique. Lipohypertrophy was present in 64.4% of them. The relationship to rotation was stark: "of the patients who correctly rotated sites, only 5% had LH while, of the patients with LH, 98% either did not rotate sites or rotated incorrectly." The same study found risk rising significantly when needles were reused more than five times.[2] Read that 98% figure carefully, because it contains two different failures. Some of those patients did not rotate. Others rotated, and rotated incorrectly. Intending to rotate and actually rotating turn out to be separable things, and a questionnaire filled in at the appointment cannot tell them apart. A contemporaneous record can. As for why clinicians care about the tissue itself, a crossover study in patients with type 1 diabetes injected insulin into lipohypertrophic tissue and into normal adipose tissue in the same people. Absorption into the affected tissue was reduced, and the variability between one injection and the next rose sharply: the coefficient of variation for insulin exposure was 52% in lipohypertrophic tissue against 11% in normal tissue.[3] The consistency was the casualty, not just the amount. The FITTER recommendations, written and vetted by 183 diabetes experts from 54 countries, summarize the position this way: "lipohypertrophy is a frequent complication of therapy that distorts insulin absorption, and, therefore, injections and infusions should not be given into these lesions and correct site rotation will help prevent them."[4] ## The part most GLP-1 articles skip Every clinical source above studied insulin. StatPearls is describing insulin-associated lipodystrophy. The 430-patient prevalence study enrolled insulin-injecting patients. The crossover study used insulin lispro in type 1 diabetes. FITTER is a set of insulin delivery recommendations. The UK regulator's 2020 safety communication on injection site lumps is likewise addressed to insulin, and it advises professionals to "remind patients to rotate injection sites within the same body region."[5] Semaglutide is not insulin. Its US prescribing information directs subcutaneous injection "in the abdomen, thigh, or upper arm" and instructs patients "to use a different injection site each week when injecting in the same body region."[6] The instruction to vary sites is there in the label. What the label does not do is present it as lipohypertrophy prevention, and the body of evidence quantifying lipohypertrophy risk was not built on GLP-1 receptor agonists. This is worth saying plainly because most rotation content in this space silently imports insulin findings and presents them as GLP-1 facts. The honest position is narrower: the labeled instruction to vary your site exists, the detailed risk research comes from a different drug class, and how much of it transfers is a question for the person who prescribed to you, not for an article. Notice also what the label's regions are. Abdomen, thigh, upper arm. If you have seen a rotation chart that routes you somewhere else, that chart is not coming from semaglutide's labeling. ## Why your memory is not the record The gap this closes is specific. A clinician sees you at intervals. Between visits, the only continuous record of where your injections went is the one you make at the time. When they ask "where do you usually inject," what they get is a reconstruction: recent injections weighted heavily, unusual weeks forgotten, the answer shaped by what you think the right answer is. When you can open six months of entries instead, the conversation changes from an estimate to a record. It also lets them answer a question a chart cannot: not what you were supposed to do, but what happened on the weeks that went badly. The UK safety communication adds a reason this record has value beyond the appointment itself. Read it precisely, because it is addressed to insulin throughout. It advises patients "to contact their doctor if they are currently injecting insulin into a 'lumpy' area before changing injection site since a sudden change may result in hypoglycaemia," and "to monitor carefully blood glucose after a change in injection site and that dose adjustment of insulin or other antidiabetic medication may be needed."[5] Nothing in that is a statement about GLP-1 dosing, and it should not be read as one. What carries across is the shape of the thing: changing where you inject is treated there as a clinical event with follow-up attached, not a housekeeping decision. A log is how you and your clinician can see when one happened and what surrounded it. ## What actually makes a site log useful Most of what people add to a tracking app is noise by the six-month mark. The fields that hold up are few: **Date and time.** Enough to reconstruct sequence and interval, which is what "rotation" means in practice. **A specific location, not a region.** "Abdomen" is nearly useless after six months because it collapses left, right, upper and lower into a single word. Peptyn's body map records eight discrete sites: left and right abdomen, thigh, glute, and deltoid. Which of those are appropriate for your medication is determined by that medication's labeling and your prescriber, not by the map's coverage. Those eight cover the whole compound library rather than any one medicine, so the map's coverage is wider than the regions your own label names. Be aware of what the app deliberately does not do with them: it pre-selects nothing and proposes no site. It does not know your label, your anatomy, or anything a clinician has told you, and most of the compounds it covers have no approved labeling at all, so it has no source for that choice. What the log screen shows instead is the site you recorded last, marked in amber, and, where the compound does have approved labeling, the regions that labeling names with a link to the label itself. Treat that as a readback of your own entries and a pointer to the source document, not as advice about where this medicine belongs. **Somewhere to put the exceptions.** Two words on the weeks that were unusual is worth more than a scale from one to ten that you fill in mechanically. The exceptions are what a clinician wants to interrogate. Peptyn has no free-text field, so that part belongs wherever you already keep notes. What does not survive the six-month test is anything requiring interpretation at the moment of entry. Records that ask you to judge severity or predict consequence get filled in inconsistently, and inconsistent data is worse than absent data because it looks trustworthy. ## Questions worth bringing with the log A six-month record is most useful when it turns into specific questions. Reasonable ones to raise with your prescriber: - Which sites does my medication's labeling permit, and does that differ from what I have been doing? - Looking at my record, is there an area concentrated enough that you want to examine it? - Can you check my sites by palpation rather than inspection, given what the literature says about detection? - If you find something, what should change, and how should I record whatever we change? - After a site change, is there anything you want me to watch or report? Every one of those is a question for a clinician. None of them is answered by an app, a chart, or this article. ## What your log cannot tell you It cannot tell you whether lipohypertrophy is present. That requires an examination by someone qualified to perform it, and the sources above are explicit that looking is not sufficient. It cannot tell you which sites you should use. Ranking the eight by which one you have left alone longest reports your own history back to you; it is not a clinical opinion about where this medication belongs on your body, and the app has no way to form one. Which sites are appropriate comes from your prescribing information and the person who prescribed to you. It cannot tell you what a pattern means. A record showing heavy concentration in one area is not a diagnosis and not a prediction. It is a prompt for a conversation with someone who can examine you. What it can do is remove guesswork from that conversation. After six months, you stop estimating and start reporting. That is the entire job of a log, and it is the one thing the chart on the poster cannot do for you. ## References 1. Quinn L, Chauhan A, Purcell S. Lipodystrophies. StatPearls. NCBI Bookshelf. 2. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013 Oct. 3. Famulla S, Hövelmann U, Fischer A, et al. Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control. Diabetes Care. 2016 Sep. 4. Frid AH, Kreugel G, Grassi G, et al. New Insulin Delivery Recommendations. Mayo Clin Proc. 2016 Sep;91(9):1231-55. 5. Medicines and Healthcare products Regulatory Agency. Insulins (all types): risk of cutaneous amyloidosis at injection site. Drug Safety Update, 23 September 2020. 6. Ozempic (semaglutide) injection, prescribing information. Novo Nordisk, via DailyMed. ## Keep reading - [The GLP-1 tracking spreadsheet: eight fields that matter](https://peptyn.orlyn.ai/articles/glp1-tracker-spreadsheet) The eight columns worth keeping, what each one answers months later, and the three moments a spreadsheet stops being the right tool. - [What to bring to a GLP-1 follow-up](https://peptyn.orlyn.ai/articles/glp1-follow-up-visit-packet) How to turn your own records into a one-page packet, and which questions are worth a prescriber's time. - [The glossary that will not do your math](https://peptyn.orlyn.ai/articles/peptide-glossary) Plain definitions from lyophilized to 503A, with sources. It defines every term and stops where the arithmetic starts. This article is educational. It does not recommend doses, schedules, or products, and it is not medical advice. Every factual claim above is linked to its source. Questions about your own protocol belong with the prescriber who wrote it. --- Source: